Protocol I8F -MC-GPGG(b)  
 
Title : Pharmacokinetics of LY3298176 Following Administration to Subjects with Impaired Renal 
Function  
 
NCTID : [STUDY_ID_REMOVED] 
 
Approval Date : 03-May -2019 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 1
LY3298176Protoco l I8F-MC-GPGG(b)
Pharmacokinetics of LY3298176 Following A dministration 
to Subjects with Impaired Renal Function
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_506228]3298176 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidenti al information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries .  
LY3298176
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Clinical Pharmacology Protocol Electronically Signed and Approved by [CONTACT_11007] : 
15January 2018
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007] :  08 June 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_82356] .  
Approval Date: 03-May-2019 GMT
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 2
LY3298176Table of Contents
Pharmacokinetics of LY3298176 Following A dministration to 
Subjects with Impaired Renal Function
Section Page
Protocol I8F-MC-GPGG(b) Pharmacokinet ics of LY3298176 Following 
Administrati on to Subj ects with Impaired Renal  Function................................................... [ADDRESS_1129021] ivities....................................................................................................... 10
3.Introduction...................................................................................................................... 13
3.1.Study Rationale............................................................................................................ 13
3.2.Background .................................................................................................................. 13
3.3.Benefit/Risk Asse ssment.............................................................................................. [ADDRESS_1129022] .................................................................................. 26
6.3.Lifestyle and/or Dietary Requirements ......................................................................... 26
6.3.1. Meals and Dietary  Restrictions............................................................................. 26
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 3
LY32981766.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 26
6.3.3. Activity................................................................................................................ 27
6.4.Screen Failures ............................................................................................................. 27
7.Treatment .......................................................................................................................... 28
7.1.Treatment Administered ............................................................................................... 28
7.1.1. Pac kaging and Labeling ....................................................................................... 28
7.2.Method of Treatment Assignment ................................................................................ 28
7.2.1.Selection and Timing o f Doses............................................................................. 28
7.3.Blinding....................................................................................................................... 29
7.4.Dose Modificat ion........................................................................................................ 29
7.5.Preparation/Handling/Storage/Accountabilit y............................................................... [ADDRESS_1129023] to Follow -up........................................................................................... 32
9.Study Assessments and Procedures ................................................................................... 33
9.1.Efficacy Assessments ................................................................................................... 33
9.2.AdverseEvents............................................................................................................ 33
9.2.1. Serious Adverse Events ........................................................................................ 34
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 34
9.2.2. Complaint Handling ............................................................................................. 35
9.3.Treatment of Overdose .................................................................................................35
9.4.Safety........................................................................................................................... 35
9.4.1. Clinical Laboratory  Tests..................................................................................... 35
9.4.2. Amylase and Lipase Measurements ...................................................................... 35
9.4.3. Glucose Moni toring............................................................................................. 35
[IP_ADDRESS]. Hyperglycemia and Hy poglycemia Reporting ................................................. 35
[IP_ADDRESS]. Severe Hypoglycemia ..................................................................................... 37
9.4.4. Vital Signs........................................................................................................... 37
9.4.5. Electrocardiograms .............................................................................................. 37
9.4.6. Injection-site Reactions........................................................................................ 38
9.4.7. Safety Monitoring................................................................................................ 38
[IP_ADDRESS]. Hepatic Safety................................................................................................ 38
9.5.Pharmacokinet ics......................................................................................................... 39
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129024] ics.......................................................................... 42
10.3.Statistical Analyses ...................................................................................................... 42
10.3.1. Safety Analyses.................................................................................................... 43
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 43
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 43
[IP_ADDRESS]. Injection-site Reactions................................................................................... 43
10.3.2. Pharmacokinet ic Analyses.................................................................................... 43
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 43
[IP_ADDRESS]. Pharmacokinet ic Statistical Inference ............................................................. 43
10.3.3. Pharmacodynamic Analyses ................................................................................. 44
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 44
10.3.5. Evaluation of Immunogenicit y............................................................................. 44
10.3.6.Data Review During the Study ............................................................................. 45
10.3.7. Interim Analyses .................................................................................................. 45
11.References ........................................................................................................................ 47
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129025] ion Classificat ion for Primary  Analyses ............................... 44
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129026] of Figures
Figure Page
FigureGPGG.1. Illustration of study design for Groups 1 to 4. ......................................... 18
FigureGPGG.2. Illustration of study design for Group 5. ................................................. 19
FigureGPGG.3. Interim data review decisio n tree............................................................ 46
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129027] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 49
Appendix 2 . Clinical Laboratory  Tests........................................................................ 52
Appendix 3. Study Governance, Regulatory  and Ethical Considerati ons..................... 53
Appendix 4. Hepatic Monitoring Tests for Treatment -emergent Abnormalit y.............56
Appendix 5. Blood Sampling Summary ...................................................................... 57
Appendix 6. Pancreatic Monitoring ............................................................................ 58
Appendix 7. Permitted Concomitant Medication ......................................................... 60
Appendix 8. Calculation o f Estimated Gl omerular Filtration Rate............................... 61
Appendix 9. Protocol Amendment I8F -MC-GPGG(b) Summary 
Pharmacokinet ics of LY3298176 Fo llowing Administration to 
Subjects with Impaired Renal Funct ion................................................... 62
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 8
LY32981761.Protocol Synopsis
Title of Study:
Pharmacokinetics of LY3298176 Following Administration to Subjects with Impaired Renal Function
Rationale:
LY3298176 is a balanced glucose -dependent insulinotropic polypeptide and glucagon -like peptide -[ADDRESS_1129028] being developed as a weekly treatment of hyperglycemia in patients with type 2 diabetes mellitus 
(T2DM).  Renal failure is a common sequelae of diabetes; it is therefore important to understand the influence of 
differing degrees of renal impairment on th e pharmacokinetics (PK) of LY3298176.
Objectives/Endpoints:
Objectives Endpoints
Primary
To estimatethe PK parameters of LY3298176 in 
subjects with mild, moderate, or severe renal 
impairment, and in subjects with ESRD after a single 
5-mg SC dose of LY3298176 compared to control 
subjects with normal renal function.LY3298176 PK par ameters, including
AUC0-∞, AUC0-tlast, and Cmax
Secondary
To assess the tolerability of LY3298176 in subjects 
with mild, moderate, or severe renal impairment, and 
in subjects with ESRD after a single 5 -mg SC dose of 
LY3298176 compared to control subjects with normal 
renal function.Adverse events
Abbreviations: AUC0-∞= area under the concentration versus time curve from time zero to infinity; 
AUC0-tlast=area unde r the concentration versus time curve from time zero to the time of last measured 
concentration ;Cmax= maximum drug concentration; ESRD =end-stage renal disease; PK = pharmacokinetic; 
SC = subcutaneous.
Summary of Study Design:
Study I8F-MC-GPGGis a Phase 1, multicenter, nonrandomized, open-label, parallel-designstudy insubjects with 
mild, moderate, or severe renal impairment ,or end-stage renal disease (ESRD),and control subjects with normal 
renal function. Renal function will provide the basis for assignment to treatment group.
Group 1: control subjects with normal renal function ( estimated glomerular filtration rate [ eGFR]
≥90mL/min/1.73m2)
Group 2: subjects with mild renal impairment ( eGFRbetween 60 and89mL/min/1.73m2)
Group 3:  subjectswith moderate renal impairmen t (eGFR between 30 and 59 mL/min/1.73m2)
Group 4:  subjects with severe ren al impairment (eGFR <30mL/min/1.73m2and not requiringdialy sis)
Group 5:  subjects with ESRD (have received dialysis for at least 3 months ).
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129029]:  
Subjects will be screened over a 28-day period prior to dosing.  Subjects will be admitted to the clinical research unit 
(CRU) on Day -1, receive a single subcutaneous injection of LY3298176 on Day1, remain at the CRU until 
discharge on Day 5, and return to the CRU on Days [ADDRESS_1129030] 28days postdose for final PK and study 
assessments.
Subjects will receive either 5 mg LY3298176 or, depending on interim analysis results, a dose of LY3298176 
reduced by [CONTACT_3450] 50% .
Number of Subjects :
Approximately 58 subjects will be enrolled so that approximately 48 subjects complete the study, such that
approximately 8subjects per group complete Groups 2 through 5.  Approximately 16completers are ne ededfrom
Group 1 in order to facilitate demographic matching with the subjects in other groups.
Statistical Analysis:
Pharmacoki netics:  The primary parameters for analysisare area under the concentration versus time curve (AUC) 
from time zero to infinity (AUC0-∞), AUC from time zero to the time of last measured concentration (AUC 0-tlast), 
and maximum drug concentration ( Cmax); log transformation will be applied. An analysis of variance model with 
subject group as fixed factor will be used in the main analyses.  The 90% confidence interval of the ratio between 
each impaired renal function group versus the control group will be estimated. Additional supportive analysis is the 
evaluation of the relationship between the PK of LY3298176 and mean eGFR,as determined by [CONTACT_815435].  Scatter plots of PK parameter versus eGFR will be produced and 
analyzed using either a mixed -effects linear or a nonlinear regression approach with eGFR as a continuous cova riate 
on PK parameters.  
Safety:  Descriptive statistics will be used to summarize safety parameters.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 10
LY32981762.Schedule of A ctivities
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 11
LY3298176Study Schedule Protocol I8F-MC-GPGG
Screening Study DaysFollow-up 
or EDComments
ProcedureDays -28
to -1Day 
-1Day 1Day 
2Day 
3Day 
4Day 
5Day 
8Day 
15Day ≥[ADDRESS_1129031] Discharge 
from CRUX Subjects may stay longer at theinvestigator ’s
discretion.
Outpatient Visit XX X
Medical History X
Physical Examination X X XX XAfter screening, medical assessment only performed to 
include medical review and targeted examination, as 
appropriate.
Weight X X X
Height X
Temperature X X
Urine Drug Screen X X XX
Ethanol Testing X XX
Safety 12-lead ECG
(hours)X Predose [ADDRESS_1129032] be 
supi[INVESTIGATOR_17044] 5 to 10 minutes before ECG 
collection, and remain supi[INVESTIGATOR_105305].
Supi[INVESTIGATOR_133634]
(hours)X XPredose, 
[ADDRESS_1129033] X X XX Female subjects only.  See Appendix 2 for details.
AEs/Concomitant 
MedicationsX XXXXXXXX X
Pharmacogenomic 
SamplePredose Single sample for pharmacogenetic analysis.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 12
LY3298176Screening Study DaysFollow-up 
or EDComments
ProcedureDays -28
to -1Day 
-1Day 1Day 
2Day 
3Day 
4Day 
5Day 
8Day 
15Day ≥28
Anti-LY3298176 
Antibodies (hours)Predose 336 XTime-matched PK sample should be collected at each 
time point .  
In the event of drug hypersensitivity reactions 
(immediate or non -immediate), samples will be 
collected as close to event onset as possible, at event 
resolution, and 30 days following the event.  Subjects
with TEADA at follow -up/ED will undergo additional 
follow-up.  SeeSection9.6.1for details.
Glucose Monitoring
(hours)Predose, 
12 24487296168336 XPerformed using a bedside glucose monitor.  
Additional measurements may be taken at the 
discretion of the investigator as clinically indicated.
PK Sampling (hours) Predose, 
8, 12 24487296168336 XUp to a 10% deviation from the nominal collection 
time is permissible.
Assessment of 
Injection-site 
Reactions (hours)Predose, 
0, 6, 122448 0-hour assessment should be performed within 
approximately 5 minutes after subcutaneous injection.  
Additional assessments may be performed if deemed 
necessary by [CONTACT_093].
Abbreviations:  AE = adverse event; CRU = clinical research unit; ECG = el ectrocardiogram; ED = early discontinuation; PK=pharmacokinetic (s); 
T2DM= type 2 diabetes mellitus ; TE ADA = treatment -emergent antidrug antibodies .  
Note:  All sampling times are given relative to dosing with LY3298176 (predose or hours postdose).
Note:  If multiple procedures take place at the same time point, the following order of the procedures should be used:  ECGs, vital signs, clinical laboratory 
sample, and PK sample, with PK sampling time the priority .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 13
LY32981763.Introduction
3.1.Study Rationale
Study I8F-MC-GPGG is a Phase 1, multicenter, nonrandomized, open -label, parallel -design 
study in subjects wi th mild, moderate, or severe renal impairment ,or end-stage renal disease 
(ESRD),andcontrol subjects with normal renal funct ion.  
LY3298176is currently being invest igated for its use in the treatment of hyperglycemia in 
patients with type 2 diabetes mellitus ( T2DM).Renal failure is a commo n sequelae of diabetes; 
it is therefore important to understand the influence of differing degrees of renal impairment on 
the pharmacokinet ics (PK)of LY3298176.  The primary purpose of this study is to determine the 
PK ofa single subcutaneous ( SC)dose of LY3298176 in subjects with renal impairment 
compared to subj ects with normal renal function.  The results of this study  will be used to 
support appropriate dose recommendat ions in patients with T2DM wi th varying degrees of renal 
impairment.
3.2.Background
In normal physiologyfollowing a meal , the incret ins glucagon-like peptide -1 (GLP-1)and 
glucose-dependent insulinotropic polypeptide ( GIP)are secreted from enteroendocrine cells in 
the gut to enhance the physio logical responses to f ood intake ,including insulin secret ion, 
nutrient disposal, and the sensat ion of satiety.  It is now well established that T2DM patients 
have impaired incretin responses (Nauck et al. 2004) ,and pharmaco logic interventi ons provi ding 
either GLP-1 receptor a gonistic peptides or dipept idyl peptidase ( DPP)-IV inhibitors (which 
delay degradat ion of endogenous GIP and GLP -1) are successfully used in the treatment of 
T2DM (Drucker and Nauck 2006; Amori et al. 2007; Baynes 2010).   Although GLP-1 is 
regarded as the incretin of therapeutic ut ilityin T2DM patients, published data demonstrat esthat 
overexpressio n of GIP may lead to improved body weight and glycemic control , and the 
combination of GLP-1 and GIP m ay result in improved glycemic efficacy and weight 
managem ent compared with GLP-1 agonists alone (Kim et al . 2012; Finan et al . 2013).
LY3298176 is a lo ng-acting, dual incret in receptor co -agonist that binds to both the GIP receptor 
and the GLP -[ADDRESS_1129034] ive tissues (such as pancreatic -cellsand adipose ti ssue) that express bo th GIP 
and GLP-1 receptors .  This could maximize the intended therapeut ic benefit of increased energy 
utilization and greater weight loss while also improving glycemic control in patients with T2DM
(Baggio and Drucker 2007) .
CCI
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 14
LY3298176The safety, tolerabilit y,and PK/pharmacodynamics of LY3298176 were evaluated in a 3-part,
Phase1 clinical pharmaco logy trial, I8F-MC-GPGA (GPGA) in healthy subjects and pat ients 
with T2DM.  In StudyGPGA, LY3298176 was administered by [CONTACT_815436] a single dose of
0.25 to 8 mgto healthy subjects (Part A);as multiple doses of0.5 to 10mgto healthy subjects
(PartB);andasmultipledoses of 0.5 to 15 mgadministered to pat ients with T2DM (Part C ).  
Following administration of a single dose of LY3298176, the maximum drugconcentration 
(Cmax) was observed to occur between 8 and 96 hours. The mean terminal half- life was 
approximately  5days,thus supporting a QW dosing regimen. Pharmacokinet icdata from  the 
Phase 1 study  supports apparent dose -proportionality of LY3298176.
Based on prelimina ry data,52 subjects (out of 142 subjects dosed in this study ) received 4.5 mg 
(6healthy subjects) to [ADDRESS_1129035] dose (32 T2DM out of 47 subjects) .  
There were no reported LY3298176 -related SAEs.
Overall, gastrointestinal events (eg,vomiting, abdominal distensio n, nausea, diarrhea) werethe 
mostfrequently reported adverse events (AEs) .  These AEs increased in number and severit y 
with increasing doses, and higher doses appeared to be better tolerated when LY329 8176 was 
administe red via dose titration. The reported gastrointestinal -(GI-) related AEs are consistent 
with GLP-1 pharmaco logy and those observed previously fo llowing administration of GLP -1 
receptor agonists (RAs) (Nauck et al . 2009; Dungan et al. 2014; Giorgino et al. 2015; Jendle et 
al. 2016; Nauck et al. 2016).
In PartA (SAD) of StudyGPGA, with increasing doses there was an increase in the number and 
severity of AEs related to LY3298176 .  At the 5-mg dose, 6subjects reported a total of [ADDRESS_1129036] squares ( LS)mean time-averaged pulse rate 
change from baseline to [ADDRESS_1129037] acebo for the time -averaged change fro m baseline to 72 hours were 5.24 bmp 
in the 10-mg titration dose group in Part B, and 10.28 bmp in the 15 -mg titration dose group in 
Part C.  H owever, the increases didnotresult in any subjectdiscontinuations.  There were no 
clinically significant changes in systo lic or diastolic blood pressure (BP)or QT/corrected QT 
(QTc) interval prolongation observed in eit her healthy  subjects or patients with T2DM.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 15
LY32981763.3.Benefit/Risk Assessment
Preclinical data and the preliminary  clinical data ( see Section 3.2) from Study GPGA support 
further clinical development for LY32 [ZIP_CODE].
No clinically  significant safet y or tolerability concerns were ident ified up to the highest 
single-dose level of 8 m g or following 4 QW doses titrated up to 15 mg in Study GPGA.  Based 
on this informat ion, 5mg doses to be administered in Study  GPGG arereasonably ant icipated to
be tolerable in subjects wi th renal impairment and in controlhealthy subjects.  Subjects will 
reside in the clinical research unit ( CRU)under clo se monitoring for at l east 5 day s, with the 
option of being kept for longer; discharge fro m the CRU will be per investigator discret ion.  An 
interim analysis safet y, tolerability, and PK data is planned to d etermine whether dose 
adjustments are needed (see Section10.3.7).
For safety purposes, blood glucose levels will be mo nitored for all subjects .  Section [IP_ADDRESS]
describes glucose monitoring procedures and how epi[INVESTIGATOR_815422], if necessary .
Anyidentified potential risks are similar with the risks associated with current ly available 
long-acting GLP-1 RAs (see Section3.2), are considered to be manageable , and are able to be 
monitored.
There is no antici pated therapeuti c benefit for the subjects in this study .
More informat ion about the known and expected benefits, risks, serious AEs(SAEs),and 
reasonably  anticipated AEs of LY3298176 are to befound in the Investigator’s Brochure ( IB).
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129038] after a single 
5-mg SC dose of LY3298176 compared to control 
subjects with normal renal function.LY3298176 PK parameters, including AUC0-∞, 
AUC0-tlast,and Cmax
Secondary
To assess the tolerability of LY3298176 in subjectswith 
mild, moderate, or severe renal impairment, and in 
subjectswith ESRD after a single 5-mg SC dose of 
LY3298176 compared to control subjects with normal 
renal function.Adverse events
Exploratory
To evaluate the formation of ADA to LY3298176 after a 
single 5-mg SC doseadministered to subjects with mild, 
moderate, or severe renal impairment, and in subjects 
with ESRD .Presence of ADA toLY3298176
Abbreviations:  ADA= antidrug antibodies ; AUC0-∞= area under the concentration versus time curve from time 
zero to infinity; AUC0-tlast= area under the concentration versus time curve from time zero to the time of last 
measured concentration ; Cmax= maximum drug concentration; ESRD =end-stage renal disease; 
PK=pharmacokinetic; SC = subcutaneous.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129039] ion.  Subjects with T2DM will not be included in 
Group1.  Subjects with T2DM andrenal impairment will be permitted to enrollin Groups 2 to 5,
whereassubjects wi th T2DM andnormal renalfunction will not be permitted .  Subjects will be 
assigned to 1of 5 groups (Groups 1 to 5) based on criteria outlined in TableGPGG.2.  For 
description of enrollment order and interim analysis, see Section 10.3.7.Estimated glo merular 
filtration rate (eGFR) will be determined by [CONTACT_815437] (MDRD) 
abbreviated equation ( Appendix 8 ) using serum creatinine levels obtained at Screening and on 
Day -1; subjects will be assigned to groups based on values fro m Day-1.See Sections 5.2and 
10.1for sample size informat ion.
The control subjects (Group 1) will be selected in order that the mean and distribut ion of 
Group1 are compara ble to the m ean and distribut ion for each group with renal impairment 
(Groups 2 through 5) for age (±10 y ears),sex, race, wei ght (± 10kg), and body mass index 
(BMI) (±20%) , asfaras is practically possible (addit ional information will be provided to the
investigator sin aseparate document) (FDA 2010) .  An effort will be made to enroll control 
subjects that are representative of the races of the impaired subjects. One-to-one matching of 
subjects ( 1impaired subject m atched to 1healthy subject in 1or more impairment groups using 
the same criteria previously described) m ay be used to facilitate interim analysis.
TableGPGG.2. Subject Groups based on Renal Impairment Status
Classification eGFR (mL/min /1.73m2)
Group 1 Control (normal renal function) ≥90
Group 2 Mild renal impairment 60-89
Group 3 Moderate renal impairment 30-59
Group 4 Severe renal impairment <30 and not requiring dialysis
Group 5 End-stage renal disease Requiring dialysis
Abbreviations :  eGFR = estimated glomerular filtration rate (as determined by [CONTACT_815438] ).
FigureGPGG.1and FigureGPGG.2illustrate the study design.
Subjects will visit the CRU to sign the informed consent document and undergo screening 
procedures up to 28days prior to dosing.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129040] 28days postdose .  Clinical laboratory tests, physical examinat ion, vital signs, 12 -lead 
electrocardi ograms (ECGs),injection-site reactions, glucose monitoring,AEs, and antidrug 
antibodies (ADA)will be monitored to assess safety  and tolerability.  Blood samples for PK and 
immunogenicit y analysis will  be collected predose through the final follow-up visit.
For subjects with ESRD, administration of LY3298176 should occur at l east 24 hours pri or to the 
next planned dialysis sessio n.  Thetime and dates of dialysis sessio ns from the session 
immediately prior to dose through Day  8 will be recorded i n the case report form (CRF) .To 
eliminate potential variat ion between different ty pes of dialysis membrane, only high- flux 
polysulfo ne membranes will be used.
Study governance considerations are described in detail in Appendix 3 .
Abbreviations :  ADA = antidrug antibodies; D = Day; PK = pharmacokinetic .
FigureGPGG. 1.Illustration of study design for Groups 1 to 4.

I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 19
LY3298176Abbreviations :  ADA = antidrug antibod y; D = Day ; PK = pharmacokinetic.
FigureGPGG.2.Illustration of study design for Group 5 .
5.2.Number of Participants
Approximately  58 subjects will be enro lled so that approximately 48subjects complete the study , 
such that approximately 8subjects per group completeGroups 2 through 5 (EMEA CHMP 
2016).  Approximately 16completers are needed from Group [ADDRESS_1129041] completedthe study when all 
scheduled procedures shown in t he Schedule o f Activities (Section 2) have been finished.
5.3.End of Study Definition
End of the studyis the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Section 2) for the last subject.
5.4.Scientific Rationa le for Study Design
A comprehensive range of renal impairment is necessary to fully characterize the impact of renal 
impairment on the PK of LY3298176. Subjects undergoing dialysis (Group 5) will be included 
to determine the effect of dialysis on drug removal.
This study  has been designed in accordance with the current regulatory  guidances (EMEA 
CHMP 20 16; FDA 2010) for the study  of PK in subjects wi th impaired renal funct ion.  
LY3298176 has shown linear and dose -proportional PK,based on preliminary  SAD and MAD 
data in the Phase 1 Study GPGA.  Per FDA guidance “ a single-dose study  is satisfactory for 
cases where there is clear prior evidence that single- dose studies accurately describe the PK for 
the drug and potential lyactive metabolites”(FDA 2010) . This renal impairment study will be 
conducted as a single -dose study .Admission
DoseDischarge Follow up
Screening
Days  -28 to -1
D-1   D1  D1 D1 D2     D3       D4        D5           D8           D15           D≥28
0      8      12        24        48            72            96                168              336                 ≥ 648 
0 336                 ≥ 648 
(predose )PK and ADA Sampling
PK sampling (hours  postdose) 
ADA sampling (hours postdose) Hemodialysis†
†The first pos tdos e dialysis session should be scheduled to start at leas t 24 hours after administration of LY3298176. 
Subs equent dialysis sess ions should be s cheduled as clinically appropria te.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129042] ive, 
investigators and subjects do not need to be blinded.
Based on the molecular weight of LY 3298176, its PK may be impacted by  [CONTACT_368459] .  
However, LY 3298176 is expected to bind to albumin ( because of the C20 fatty  acid conj ugation 
structure) ,thus systemically result ing in a larger molecular size and decreasing the likelihood 
that PK will be meaningfully impacted by  [CONTACT_368459].  Thus the same dose of LY3298176
is planned to be administered to subjects in all groups.
An interim analysis each are planned fo llowing dosing of at least [ADDRESS_1129043] 2 subjects 
in Groups 4 and 5 and appropriate matched -control subjects in Group 1. An additional 
interim analysis will be done after com pletion of the Group 3 (see Section 10.3.7).  The purpose 
of the interim review(s) is to determine the dose level(s) for subsequent subjects, based on safet y, 
tolerability, and PK data.  The dose of LY3298176 for subsequent subjects (any  or all groups) 
may be adjusted accordingly after each interim. Data from the additional interim (completion of 
Group3) will support Phase 3 enrollment .
5.5.Justification for Dose
A 5-mg dose was selected based on prec linical pharmacology and toxicologydata.  In addition, 
preliminary results fro m Study GPGA indicate the 5-mg dose was relatively well tolerated by 
[CONTACT_815439] T2DM,and is expected to be a clinically meaningful dose .  In 
Study GPGA Part A (SAD), [ADDRESS_1129044] 2subjects in each of the mild and moderate renal 
impairment groups and appropriate matched- control subjectswill be used to determine whether 
to continueadminister ingthe 5-mg dose to the remaining subjects (see Section 10.3.7).  Another
review will be performed fo llowing dosing o f [ADDRESS_1129045] groups and appropriate matched- control subjects.  Both reviews will assess safet y and 
tolerability data.  The PK data will also be analyzed during the sereviews.  If it appears that the 
PK areinfluenced by [CONTACT_815440] t and the exposure in subjects with impairment is higher 
than expected or if there are safet y/tolerability events that manifest at a hi gher than expected rate 
in these subjects , then the dose would be reduced by [CONTACT_3450] 50%.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129046] meet the following criteria for enrollment (Inclusio n Criteria [1] through [6]). 
Additionalsubgroupi[INVESTIGATOR_815423] n criteria below are specific to the subjects’ renal funct ion
(Inclusion Criteria [7] through [12]) and diabetic status (Inclusion Criteria[13]through [16]).
6.1.1.Inclusion Criteria for AllSubjects
[1a]Male subjects:
Men, regardless of their fertilit y status, with non -pregnant women of childbearing 
potentialpartners m ust agree to ei ther remain abstinent (if this is their preferred 
and usual lifest yle) or use condoms plus one addit ional highly effective (less than 
1% failure rate) method of contraception (such as combinat ion oral 
contraceptives, implanted con traceptives, or intrauterine device) or effect ive 
method of contraception (such as diaphragms wit h spermicide or cervical sponge) 
for the durati on of the study  anduntil their plasma concentrations are below the 
level that could result in a relevant potent ial exposure to a possible fetus, 
predicted to be approximately 30 days following dose of study  drug (bel ow the 
no-observed-adverse-effect level [NOAEL]/10).
oMen and their partners may  choose to use a double -barrier method of 
contraception.  Barrier protec tion methods wi thout concomitant use of a 
spermicide are not an effect ive or acceptable method of contraception.  Thus, 
each barrier method must include use of a spermicide.  It should be noted,
however,that the use of male and female condoms as a double -barrier method 
is not considered acceptable due to the high failure rate when these barrier 
methods are combined.
oPeriodic abstinence (eg, calendar, ovulat ion, symptothermal, post -ovulation 
methods), declaration of abst inence just for the duration of a tri al, and 
withdrawal are not acceptabl e methods of contraception.
Men with pregnant partners should use condoms during intercourse for the 
duration of the study  and until the end of estimated relevant potential exposure in 
women of childbearing pote ntial (below the NOAEL/10) .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 22
LY3298176Men who are in exclusively same sex relat ionships (as their preferred and usual 
lifestyle) are not required to use contraception.
Men should refrain fro m sperm donation for the durati on of the study  and until 
their plasma concentrations are below the level that could result in a relevant 
potential exposure to a poss ible fetus, predicted to be approximately 30 days 
following dose of study  drug (bel ow the NOAEL/10) .
[1b]Female subjects:
Women of childbearing poten tial are excl uded from thestudy.
Women not of childbearing potential may participate and include those who are:
A.infertile due to surgi cal sterilizat ion (hysterectomy, bilateral oophorectomy ,or 
tubal ligation), congenital anom aly such as m ullerian agenesis; or
B.postmenopausal –defined as eit her:
i.A womanat least [ADDRESS_1129047] uterus , not on hormone 
therapy, who has had either :
a)cessation of menses for at least 1 y ear, or
b)at least 6months of spontaneous amenorrhea with a 
follicle-stimulating hormone >40IU/mL;or
ii.A woman [ADDRESS_1129048] 
6months of spontaneous amenorrhea; or
iii.A woman at least 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy .
[2]Are between the ages of 18 and 85 y ears, inclusive.
[3]Are between the BMI of 19.0 and 40.0 kg/m 2,inclusive, at screening.
[4]Have venous access sufficient to allow blood sampling as per the protocol.
[5]Are reliable and willing to make themselves available for the duration of the 
study and are willin g to follow study  procedures.
[6]Have given written informed consent approved by [CONTACT_815441] (ERB)governing the site.
6.1.2.Additional Inclusion Criteria for Control Subjects
[7]Healthy males or females as determined by [CONTACT_9870] , physical 
examination, and other screening procedures, with normal renal funct ion, 
assessed by  [CONTACT_67889]≥90 mL/min at screening.
[8]Have clinical laboratory  test resul ts within norm al reference range for the 
population or invest igator site, or results with acceptable dev iations that are 
judged to be not clinically significant by  [CONTACT_093] .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 23
LY3298176[9]Have norm alBP and pulse rate, as determined by  [CONTACT_093].
6.1.3.Additional Inclusion Criteria for Subjects with Mild to Severe 
Renal Impairment or ESRD
[10]Males or females wit h stable mild to severe renal impairment, assessed by 
[CONTACT_815442] (having received dialysis for at least 3 months).
[11]Clinical laboratory  test resul ts with deviations that are judged by [CONTACT_815443] s study.
[12]Have acceptable BP and pulse rate , as determined by [CONTACT_093] .
6.1.4.Additional Inclusion Criteria for Subjects with T2DM and Renal 
Impairment or ESRD
[13]Have T2DM treatedwith diet or exercise alone or with stabledoses of
metforminand/orinsulinsfor at least 8 weeks.
[14]Subjectstaking stable doses of over -the-counter or prescription medicat ions 
(eg, antihypertensive agents, aspi[INVESTIGATOR_248], lipid -lowering agents) for treatment of 
concurrent medical condit ions are permitted to participate providing they  
have been stable on their treatment regimen for at least 4 weeks.
[15]Have ahemoglobin A1c (HbA1c) ≥6.0% and ≤11.0%at the screening visit .
[16]Have clinical laboratory  test resul ts within norm al range or deem ed clinically  
insignificant by  [CONTACT_3170]. Abnormalit ies of serum glucose, serum 
lipi[INVESTIGATOR_805], urinary  glucose, and urinary  protein consistent wi th T2DM are 
acceptable.
6.2.Exclusion Criteria
Subjects willbe excluded fro m study enrollmentif they meet any o f the following criteria at 
screening and/or enrollment .  For all subjects, Exclusion Criteria [17] through [ 42] apply; 
additionalsubgroupi[INVESTIGATOR_815424] e subjects’ renal funct ion 
(Exclusion Criteria [43] through [ 45])and diabet ic status (Exclusion Criteria [ 46] through [ 49]).
6.2.1.Exclusion Criteria for All Subjects
[17]Are invest igator site personnel directly affiliated wit h this study  and their 
immediate families. Immediate family is defined as a spouse, parent, child ,
or sibling, whether bio logical or legally adopted.
[18]Are Lilly employees.
[19]Are current ly enrolled in a clinical study  involving an investigational product 
(IP)or any other type of medical research judged not to be scient ifically or 
medically co mpatible with this study.
[20]Have known allergies to LY3298176 or related compounds.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 24
LY3298176[21]Have a history  of atopy or clinically significant m ultiple or severe drug
allergies, intolerance to topi[INVESTIGATOR_11930], or severe posttreatment
hypersensit ivity reactions (including, but not limited to, erythema mult iforme
major, linear immunoglobulin A dermatosis, toxic epi[INVESTIGATOR_47423], or 
exfoliative dermat itis).
[22]Have previously co mpleted or withdrawn fro m this study  or any other study  
investigat ing LY3298176.
[23]Persons who have a current, functioning organ transplant .  Nonfunctional 
renal allografts may be allowed .
[24]Have a person al or family history  of medullary thyroid carcinoma or have
multiple endocrine neoplasia syndro me type 2.  
[25]Febrile illness within 3 days prior to screening.
[26]Have a history of second-or third-degree heart block or any  abnormality in 
the 12-lead ECG at screening that, in the opi[INVESTIGATOR_3078] n of the invest igator, 
increases the risks associated with participat ing in the study.
[27]Have asignificant history or presence of cardiovascular ( eg, myocardial 
infarction, cerebrovascular accident, etc . within the past 6 months ), 
respi[INVESTIGATOR_696], hepatic, renal(applies to Group 1 only) , GI,endocrine (except 
T2DM), hem atological, or neurol ogical disorders capable of significant ly 
altering the absorpti on, metabolism, or eliminat ion of drugs ; of constituting a 
risk when taking the st udy medication; or of interfering with the 
interpretation of data.
[28]Show evidence of significant active neuropsychiatric disease.
[29]Have a history  of malignancy wit hin 5years prior to screening.
[30]Have a history  or presence of pancreat itis (history of chronic pancreatitis or
idiopathic acute pancreat itis), elevat ion in serum amylase or lipase or GI 
disorder (eg, relevant esophageal reflux or gall bladder disease) or any  GI 
disease which impacts gastric emptying (eg, gastric by[CONTACT_4897] , pyloric 
stenosis, withthe exception of appendectomy) or could be aggravated by 
[CONTACT_34046]-1 analogs or DPP-IV inhibitors. Subjectswith dyslipi[INVESTIGATOR_815425] (removal of gall stones) and/or 
cholecystectomy (remo valof gall bladder) in the past, with no further 
sequelae, may be included in the study  at the discretion of the investi gator.
[31]Have serum aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) >2× the upper limit of normal ( ULN)or total bilirubin (TBL)>1.5×
ULN.
[32]Have a serum triglyceride ≥5 mmol/L (442.5 mg/dL) at screening.
[33]Show evidence of human immunodeficiency virus (HIV) and/or positive 
HIV antibodies.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 25
LY3298176[34]Show evidence of hepat itis C and/or posit ive hepatit is C antibody .
[35]Show evidence of hepat itis B and/or posit ive hepatit isB surface ant igen.
[36]Are women with a positive pregnancy test or women who are lactating.
[37]Regularly use known drugs of abuse and/or show posit ive findings on 
urinary drug screenthat are not otherwise explained by  [CONTACT_815444].
[38]Intend to use:
a.over-the-counter m edication within 7 days prior to dosing.
b.prescription medication (other than those listed in Section 7.7and 
Appendix 7 )within [ADDRESS_1129049] igator.
[39]Have donated blood of more than 450mL within the last month.
[40]Have an average weekly alcoho l intake that exceeds 21 units per w eek 
(males up to age 65) and 14 units per week (males over 65 and females), and 
are unwilling to stop alcoho l consumpt ion 24 hours prior to dosing unt il 
discharge from  the study  or completion of all study procedures (1 unit = 
12oz or 360 m L of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of 
distilled spi[INVESTIGATOR_2120]).
[41]Are unwilling to refrain from smoking on the day of LY3298176 
administration or are unable to abide by [CONTACT_815445].
[42]Aredetermined to be unsuitable by  [CONTACT_109307].
6.2.2.Additional Exclusion Criteria for Subjects with Mild to Severe 
Renal Impairment or ESRD
[43]Have hemoglobin <8.5 g/dL or si gnificant active hematological disease from 
causes other than underlying renal disease.
[44]Have used any drug indicated for medical care of the subject’s renal 
impairment, which is not established in dose and administered for at least 
7days before LY3298176 administration .
[45]Positive findings on ethano l testing and use of drugs of abuse and/or posit ive 
findings on urinary  drug screenexcept tho se prescribed for related 
complications (ie, pain, inso mnia, anxiet y) of renal disease .  A serum or 
salivary drug screen may be performed on subjects who are unable to 
produce a urine sample.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129050]
[46]Have taken any  glucose-lowering medicat ions other than metformin and/or
insulins(refer to Inclusion Criterion[13]) in the past 3 months before 
screening .In general, stable dosages of metformin and insulins will be 
continued; however, a washout period or dose modificat ions may be 
necessary  to allow for optimal blood glucosemonitoring throughout the 
dosing period at the discretion of the invest igator.
[47]Have had more than [ADDRESS_1129051] dose of study  drugshould also be excluded .
[48]Have had a blood transfusio n or severe blood loss or have known 
hemoglobinopathy (alpha -thalassemia), hemo lytic anemia, sickle cell 
anemia, or any  other condi tion known to interfere with HbA1c methodology .
[49]Have received chronic (last ing >14 consecut ive days) systemic 
glucocorticoid therapy (excluding topi[INVESTIGATOR_2855], intra -articular, and inhaled 
preparations) in the past y ear or have received any glucocorticoid therapy 
within 30 days before screening.
6.3.Lifestyle and/or Dietary Requirements
Throughout the study , subjects m ay undergo medical assessment sand review of compliance with 
requirementsbefore continuing in the study .
6.3.1.Mealsand Dietary Restrictions
Subjects will be required to fast overnight for at least 8 hours before being given anSC dose of 
LY3298176 , and when clinical laboratory  testsamples are taken (see Schedule o f Activities 
[Section2]).Water may be consumed freely. Standard meals will be administered while 
subjectsare resident at the CRU.
6.3.2.Caffeine, Alcohol, and Tobacco
No alcohol will be allowed from [ADDRESS_1129052] consume no more than 10 cigarettes or the equivalent per 
day.
Subjects will be allowed to m aintain their regular caffeine consumpt ion throughout the study 
period.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 27
LY32981766.3.3.Activity
Subjects should not engage in strenuous physical exercise or activitiesfrom 48 hours prior to 
dosing unt ildischarge from  the studyor completion of all study  procedures .  When certain study  
procedures are in progress at the site, subjects may be required to remain supi[INVESTIGATOR_103169].
6.4.Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failu re) may notbe 
rescreened .  
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129053] ered
LY3298176 will be administered at the CRU as a single SC injection of either 5 mgor, 
depending on the results of interim analysis, a dose reduced by  [CONTACT_3450] 50% .  Instructions 
for preparation and handling are summarized in Section 7.5.
Whenever possible, study  drug administrati on should be carri ed out by [CONTACT_14030].  
Dosing will co mmence at approximately the same time of day in all dose groups.  The actual 
time of dosing will be recorded in the subject’s CRF.
The investigator or designee is responsible for:
explaining the correct use of the IPto the site personnel
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
and returning all unused medicat ion to Lilly or its desig nee at the end of the study .
Note: In some cases, sites may destroy  the material if, during the invest igativesite selection, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials.  
7.1.1.Packaging and Labeling
Clinical trial materials will be label edaccording to the country ’s regulatory requirements.  
LY3298176 will be supplied by  [CONTACT_643936] h lot numbers .
LY3298176 is supplied as 5-mg lyophilized powderin a glass vial intended for single -dose
administration .  When reconstituted according to instructions, t he LY3298176 solut ion should be 
clear,colorless,and free of any visible p articulate matter.
Apharmacist at the site or other site personnel will use the vials provided to prepare the sy ringes.
7.2.Method of Treatment Assignment
Subjects will be assigned to groups based on mean eGFRas determined by  [CONTACT_815446] -1(see TableGPGG.2).The 
allocation and dispensing of the IPwill be fully documented and verified by a second person.  
Detailed records of the amounts of the IPreceived, dispensed, and remaining at the end o f the 
study will be maintained by [CONTACT_7232].
7.2.1.Selection and Timing of Doses
A singledose will be administered by [CONTACT_815447] 1.  
The site of injection administrati on will be recorded .  
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129054] 2 subjects each 
with mild and m oderate renal impairment (Group 2 and Group 3, respectively) and appropriate 
matched-control subjects (Group 1) ,  aninterim analysis, to include safet y, tolerability, and PK 
data, is planned ( Section 10.3.7andFigureGPGG.3).  Safety data will be reviewed by  [CONTACT_815448] a regular basis while subjects are enrolled in the study.   After dosing of the first 
2subjects with severe renal impairment and ESRD (Groups 4 and 5) and appropriate 
matched-control subjects (Group 1) , anotherinterim analysis will be perform ed.  The purpose of 
the interim review(s) is to determine the dose level(s) for subsequent subjects.  The dose of 
LY3298176 for subsequent subjects (any or all groups) may  be adjusted accordingly  after each 
interim review.  The final dose determi nations will be made by [CONTACT_815449].
7.5.Preparation/Handling/Storage/Accountability
LY3298176 lyophilized powder is to be reconstituted with Sterile Water for Inject ion (United 
States Pharmacopoeia).  The reconst ituted product so lution in the vial(s) may be held at room 
temperature and/or refrigerated (2°C to 8°C) ,and should be administered within [ADDRESS_1129055] been 
maintained , as communicated by s ponsor,during transit for all IPreceived and any discrepancies 
are reported and resolved beforeuse of the study  treatment.
Only participants enrolled in the study  may receive IPor study materials, and only authorized 
site staff may supply or administer IP.All IPshouldbe stored in a nenvironmentally controlled 
and monitored (manual or autom ated) area in accordance wit h the labeledstorage condit ions 
with access limited to the investigator and authorized site staff .
The investigator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatment accountabilit y, reconciliat ion, and record maintenance ( such as
receipt, reconciliat ion,and final disposit ion records) .
7.6.Treatment Compliance
The IPwill be administered at the clinical site, and documentation of treatment administration 
will occur at the site.
7.7.Concomitant Therapy
Stable doses of over-the-counter or prescript ion medications (eg, antihypertensive agents, 
aspi[INVESTIGATOR_248], lipid-lowering agents) for treatment of concurrent medical condit ions areallowedfor 
subjects wi th renal impairment .  Refer to Appendix 7 for common medications prescribed to 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 30
LY3298176patients with renal impairment .  Subjectson stable concomitant medicat ion(s)at the time of 
study entry should continue their regular, unchanged dose throughout the study .  
Stable single oral  doses of m etforminand/orstable doses of insulins (for at least 8 weeks) are 
allowed for subjec ts with T2DM.  Refer to Exclusion Criterion [46] in Sect ion 6.2.3.
In the case of mild intercurrent illness during the study , concomitant treatment wi th 
paracetamo l/acetaminophen may be allo wed at the discret ion of the investigator and is to be
recorded in the CRF.
No start of new concomitant therapy , apart from  occasional intake of vitamin/mineral  
supplements, allowable ant iemetics, and acetaminophen, will be permitted for [ADDRESS_1129056] 
(CP) or clinical research physician (CRP).
Additional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatment of an ongoing medical problem.  Any drug given for the treatment of an AE should be 
documented as such.
7.8.Treatment after the End of the Study
Not applicable.  LY3298176 will n ot be made available to subjects after conclusion of the study .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129057] occur between the Lilly  CP/CRPand the invest igator to 
determine if the subjectmay continue in the study .  If both agree i t is medically appropriate to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRPto allow the 
inadvertent ly enrolled subjectto continue in the study  with or without continued treatment with 
IP.  
8.2.Discontinuation from the Study
Subjectswill be discont inued in the fo llowing circumstances:
Enrollment in any other clinical study involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpatible with this study
Participation in the study  needs to be stopped for medical, safet y, regulatory, or other 
reasons consistent with applicable laws, r egulations, and good clinical pract ice
Investigator Decisio n
othe investigator decides that the subject should be discontinued from the study
oif the subject,for any reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effective for treatment of T2DM, discontinuation 
from the study should occur prior to introducti on of the new agent
Subject Decisio n
othe subjectrequests to be withdrawn fro m the study
Adverse event
oif a clinically significant event ( CSE)occurs, the subjectis to be discont inued and 
appropriate measures taken.  Lilly  or its designee shoul d be alerted immediately.  
A CSE will be defined as a moderate -to-severe AE, abnormal clinical sign, or 
clinical laboratory  finding that may  pose a risk to the well -being of the subject
oa clinically  significant systemic hypersensit ivity reaction occurs fo llowing 
administration of the IP(eg, drug-related symptomatic bronchospasm, allergy -
related edem a/angioedema, or hy potension) that requi res parenteral medicat ion, 
does notrespond to symptomat ic medication, or results in clinical sequelae or an 
anaphylactic reaction
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 32
LY3298176At the discretion of the investigator, if the participant has 2 or more symptomat ic 
hypoglycemic epi[INVESTIGATOR_1841] (defined as an event with typi[INVESTIGATOR_815426] s 
and a measured blood gl ucose ≤63 mg/dL [3.5mmol/L], equivalent to plasma /serum
glucose ≤70 mg/dL [3.9 m mol/L];refer to Secti on9.4.3)
Fasting plasma/serumglucose values are >270 mg/dL (approximately 15 m mol/L, 
equivalent to a fast ing blood glucose > 241 mg/dL [13.4 mm ol/L]) on 3 or m ore 
separate days over any 2- week peri odbetween screening and the end of the dosing 
period
Discontinuation for abnormal pancreatictestsshould be considered by [CONTACT_53022]
a subject’s lipase and/or amylase are confirmed to be ≥3×ULN. Please refer to the
algorithm for the monitoring of pancreatic events in Appendix [ADDRESS_1129058] subjectswho fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_779].
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129059] ivities, detailingthe study procedures and their timing 
(including tolerance limit s for timing).
Appendix [ADDRESS_1129060]’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  Additionally, site personnel will  
record any  change in the condit ion(s) and the occurrence and nature of any  AEs.  
The invest igator will interpret and document whether or not anAE has a reasonablepossibility 
of being related to study treatment or a study procedure, taking into account th e disease, 
concomitant treatment ,or pathologies.  
A “reasonable possibilit y”means that there is a potential cause and effect relat ionship between 
the IP, study device ,and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs un less the underlying medical condit ion has 
worsened during the course of the study .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 34
LY32981769.2.1.Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life-threatening experie nce (ie, immediate ri sk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life threatening or result in death 
or hospi[INVESTIGATOR_815427].
Study site personnel  must alert the Lilly  CRP/CP, or designee, of any SAE as soon as pract ically 
possible.
Additionally, study site personnel  must alert LillyGlobal Patient Safet y,or its designee,of any 
SAE within [ADDRESS_1129061] 
discontinued from and/or com pleted the study (the subjectsummary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from  the study , and he/she considers the event Reasonably Possibly Related to 
the study treatment or study  participation, the investi gator must promptly notify Lilly .  
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requirements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus.
[IP_ADDRESS]. Suspect ed Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator reportsas related to IPor procedure.  Lilly  has procedures that 
will be fo llowed for the recording and expedited reporting of S[LOCATION_003]Rs that are consistent with 
global regulations and the associated detailed guidances.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129062] the investigator as soon as possible if he or she has a 
complaint or probl em with the IPso that the situ ation can be assessed.
9.3.Treatment of Overdose
For the purposes of this study , an overdose of LY3298176 is considered any dose higher than the 
assigned dose.  Treatment for overdose is supportive care (refer to IB for LY3298176) .
9.4.Safety
9.4.1.Clinical Laboratory Tests
For each subject, laboratory testsdetailed in Appendix 2 should be conducted accordi ng to the 
Schedule of Activities (Section2).  
Additional blood draws may  be drawn for safety  purposes at the investigator’s discretion.  
9.4.2.Amylase and Lipase Measurements
Serum amylase and lipase measurements will be collected as part of the clinical laboratory  
testing and as specified in the Schedule of Activit ies(Section 2).  Additional measurements may 
be perform ed at the investigator’s discretion. Further diagnost ic assessments will be 
recommended as per the algorithm (refer to Appendix 6 )for the monitoring of pancreat ic events 
whenever lipase and/or amylase is confirmed to be ≥3×ULN at any visit post dose, even if the 
subject is asymptomat ic.
9.4.3.Glucose Monitoring
For safety purposes, blood glucose measurements will be performed using a bedside glucose 
monitoras specified in the Schedule of Activities(Section 2).  Additional safety blood glucose 
measurements may  also be taken during the study  as deemed necessary  by [CONTACT_093]. 
[IP_ADDRESS]. Hyperglycemia and Hypoglycemia Reporting
Epi[INVESTIGATOR_105312] (fasting plasma/serum glucose >270 mg/dL [15 mmol/L]) or 
hypoglycemia (pla sma/serum glucose ≤70mg/dL [3.9 mmol/L]) will be reported by  [CONTACT_815450]. Additional monitoring may be requested at the invest igator’s discretion.
If the fasting plasma/serum glucose during the dosing period exceeds the acceptable level 
defined as hyperglycemia on 3 or more separate days over any 2 -week peri od between screening 
and the end o f the dosing period, the subjectwill be evaluated further a t the study  site.If fasting 
plasma/serum  glucose continues to exceed the acceptable level, the IPwill be discont inued, and 
treatment with an appropri ate antidiabetic agent may  be initiated by [CONTACT_3170].If 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 36
LY3298176hyperglycemia occurs during the fo llow-up period, the subjectwill remain in the study until 
completion of the planned fo llow-up.
Hypoglycemia epi[INVESTIGATOR_1865] s will be recorded on specific CRFpages.Hypoglycemia will be treated 
appropriately  by [CONTACT_815451]/ser um glucose l evels may 
be perform ed.The following categori es of the 2017 American Diabetes Associat ion position 
statement on glycemic targets ( ADA2017) based on recommendations of the International 
Hypoglycaemia Study  Group (IHSG2017) should b e applied for reporting in the CRFand 
evaluating hypoglycemic events.
Hypoglycemia will be described using the following definit ions:  
Documented Glucose Alert Level (Level 1), Plasma Glucose (PG) ≤70mg/dL 
(3.9mmol/L):  
oSymptomatic hypoglycemia :  an event during which typi[INVESTIGATOR_133643] ≤70mg/dL (3.9 mmol/L)
oAsymptomatic hypoglycemia: an event not accompanied by t ypi[INVESTIGATOR_133644] ≤70 mg/dL (3.9 mmol/L)
oUnspecified hypoglycemia :an event during which PG ≤70mg/dL (3.9 mmol/L) 
but no informat ion relative to symptoms of hypoglycemia was recorded
Documented Clinically Significant Hypoglycemia (Level 2) PG <54 mg/dL 
(3.0mmol/L):
oSymptomatic hypoglycemia: an event during which typi[INVESTIGATOR_815428] <54 mg/dL (3.0 mmol/L)
oAsymptomatic hypoglycemia: an event not accompanied by t ypi[INVESTIGATOR_133644] <54 mg/dL (3.0 mmol/L)
oUnspecified hypoglycemia :an event during which PG <54 mg/dL (3.0 mmol/L) 
but no inform ation relative to symptoms of hypoglycemia was recorded
Severe hypoglycemia (Level 3): an event requiring assistance o f another person to 
actively administer carbohy drate, glucagon, or oth er resuscitative act ions.  During these 
epi[INVESTIGATOR_1841], the subjecthas an altered mental status and cannot assist in their care, is 
semiconscious or unconscious, or experienced coma with or without seizures and may 
require parenteral  therapy.PG measurements m ay not be available during such an event, 
but neurologi cal recovery  attributable to the restoration of blood glucose concentration to 
normal is considered sufficient evidence that the event was induced by  a low PG 
concentration (PG ≤70 mg/dL [3.9 mmol/L])
oSevere hypoglycemia requiring medical attention :a severe hypoglycemic 
event when subjectsrequire therapy  by [CONTACT_815452] (eg, emergency 
medical technicians , emergency room personnel, etc .)
Other Hypoglycemia:
Nocturnal hypoglycemia: any hypoglycemic event (documented symptomat ic, 
asymptomat ic, probable symptomat ic, or severe hypoglycemia) that occurs between 
bedtime and waking
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 37
LY3298176Relative hypoglycemia: an event during which typi[INVESTIGATOR_10921], that 
do not requi re the assistance o f another person, are accompanied by  [CONTACT_133664] >70mg/dL 
(3.9mmol/L), but these levels may be quickly approaching the 70 mg/dL (3.9 mmo l/L) 
threshold
Overall (or total) hypoglycemia: This optional category combines all cases o f 
hypoglycemia. If an event of hypoglycemia falls into mult iple subcategories, the event is 
only counted once in this category
Probable symptomatic hypoglycemia: An event during which symptoms of 
hypoglycemia are not accompanied by a PG measurement but that was presumably 
caused by  a blood glucose concentration ≤70 mg/dL (3.9 mmol/L).
[IP_ADDRESS]. Severe Hypoglycemia
The determinat ion of a hypoglycemic event as an epi[INVESTIGATOR_815429] a subjectsimply having received assistance.
All hypoglycemic events are AEsof special interest and will be recorded in the hypoglycemia 
module of the CRF (see Section 9.2for details). All epi[INVESTIGATOR_1841] o f severe hypoglycemia must be 
reported as SAEs .  
9.4.4.Vital Signs
For eachsubject, vital signs(BP, pulse rate , and body  temperature) measurements should be 
conducted according to the Schedule of Activities (Section 2).
Blood pressure and pulse rate shouldbe measured after the subject has been supi[INVESTIGATOR_51938] 5to 10minutes.
During any AE of dizziness or posture -induced symptoms , unscheduled orthostatic vital signs 
should be assessed if possible .  If thesubjectfeels unable to stand, supi[INVESTIGATOR_80492].   Additional vital signs may be measured during thestudy if warranted.
9.4.5.Electrocardiograms
For each subject, single 12 -lead digital ECGs should be collected according to the Schedule of 
Activities (Section 2).  Electrocardi ograms m ust be recorded before collecting any  blood 
samples.
Subjectsmust be supi[INVESTIGATOR_17044] [ADDRESS_1129063] ion.  Electrocardi ogramsmay be obtained at a dditional 
times,when deemed clinically necessary .  All ECGs recorded should be stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subjectis still present, to determine whether the subjectmeets entry criteria at the relevant visit 
and for immediate subjectmanagement, should any clinically relevant findings be identified.  
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 38
LY3298176If a clinically significant findingis identified (including, but not limited to, changes in QT/QTc 
interval from baseline) after enrollment, the investigator will determine if the subjectcan 
continue in the study .  The invest igator,or qualified designee ,is responsible for determining if 
any change in subjectmanagement i s needed,and must document his/her review of the ECG 
printed at the time of collection.  Any new clinically relevant finding should be reported as an 
AEto Lilly or itsdesigneevia CRF.
9.4.6.Injection -site Reactions
For each subject, inject ion-site reactions shoul d be assessed according to the Schedule of 
Activities (Section 2).  Additional assessments may  be performed if deemed necessary  by [CONTACT_1275].
If an injection-site reactionis present, it will be fully characterized (including erythema, 
induration, pain, i tching, and swelling ) and will be cl osely monitored until  resolution.
Investigational site staff will be provided with separate instructions/training onhow to
consistent ly evaluate injection-site reactionsand their severity. Photographs of injection-site 
reactionsmay be taken in a standardized fashio n for record -keepi[INVESTIGATOR_24069]; however, the 
photographs will not be used to evaluate injection-site reactionseverity.
9.4.7.Safety Monitoring
The Lilly CPor CRP/scientist will monitor safety data throughou t the course of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly CPor 
CRPwill periodically review the following data:
trends in safety  data
laboratory  analytes including glucose, amylase, and lipase
seriousand nonserious AE s,including AEsof interest(GI events, hypoglycemia,
injection-site reactions, hypersensit ivity reactions)andreported and adjudicated 
pancreatitis
Further di agnostic assessments will be recommended whenever lipase and/ or amylase are 
confirmed to be ≥3×ULN at any  visit postdose even if the subject is asymptomatic (as per the 
algorithm for the monitoring of pancreatic events in Appendix 6 ) and,if pancreat itis is suspected, 
the case will be further defined during an adjudicatio n process.
When appropriate, the Lilly CPor CRPwill consult with the funct ionally independent Gl obal 
Patient Safety therapeutic area physician or clinical research scientist.
[IP_ADDRESS]. Hepatic Safety
If a study  subject experiences elevated ALT ≥3×ULN, alkaline phosphatase ( ALP) ≥2×ULN, or 
elevated TBL≥2×ULN, liver tests ( Appendix 4) should be repeated wi thin [ADDRESS_1129064] bilirubin , gamma-glutamyl transferase,and creatine kinaseto 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129065] igator 
based on consultation wit h the Lilly CPor CRP.  Monitoring shou ld continue until levels 
normalize and/or are returningto approximate baseline levels .  
Additional safety data should be co llected if 1or more of the following condit ions occur:  
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum  TBL to ≥2×ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2×ULN on 2or more consecut ive blood tests
subject discontinued from treatment due to a hepatic event or abnormalit y of liver
tests
hepatic event considered to be an SAE.
9.5. Pharmacokinetics
At the visits and times specified in the Schedule of Activities (Section 2), venous blood samples 
of approximately [ADDRESS_1129066] according to the Schedule of Activit ies (Section 2) to determine ant ibody 
production against LY3298176 .  Additional samples may be collected if there is a possibilit y that 
an AE is immuno logically mediated. All samples for immunogenicit y testing shoul d have a 
time-matchedsample for PKanalysis. In the event of drug hypersensit ivity reactions (immediate 
or nonimmediate), addit ional samples will be co llected as close to the onset of the event as 
possible, at the resolut ion of the event, and 30 day s following the event.  Instructions for the 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129067] an ADA sample measured at early discont inuation or at the follow -up 
visit.  A risk -based approach will be used to monit or subjects who develop treatment -emergent 
ADA (TE ADA),defined as a titer 2 -fold (1 dilution) greater than the minimum required dilut ion 
of the assay  if no ADA were detected at baseline, or a 4 -fold (2 dilut ions) increase in titer, 
compared to baseline, if ADA were detected at baseline.  
Clinically significant TE ADA will be defined as a ny TEADA at the last visit with:
a high titer (1280) or an increasing titer from last measured value
an association with a moderate-to-severe inject ion-site reaction or infusion-related 
reaction
cross-reactive and/or neutralizing binding of an ADA wit h endogenous GLP -[ADDRESS_1129068] returned to the baseline ADA titer (defined as ADA titer within 2 -fold of 
baseline). A PK sample may be collected at the follow -up immunogenicit y assessment(s), if 
warranted and agreed upon by  [CONTACT_105425].
Every attempt should be made to contact [CONTACT_263552]-up immunogenicit y assessment; 
however, if subjects are unwilling or unable to return for the visit, this is not considered a 
protocol violation.
Subjects followed for at least [ADDRESS_1129069] visit or for a shorter 
period, if local regulations and ERBsallow,at a facilit y selected by  [CONTACT_456].  The durati on 
allows the sponsor to respond to future regulatory  requests rel ated to LY3298176 .  Any samples 
remaining after 15 y ears will be destroy ed.
9.7.Genetics
A bloodsample will be collected for pharmacogenetic analysis as specified in the Sche dule of 
Activities(Section 2),where local regulat ions allow.  
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129070] subjectvisit, or for a shorter 
period iflocal regulationsand/or ERBsimpose shorter time limits , for the study  at a facility 
selected by [CONTACT_81278].  This retenti on period enables use of new techno logies, response 
to regulatory  questions, and invest igation of variable response that may  not be observed unt il 
later in the development of LY3298176 or after LY3298176 is commercially available.  
Molecular techno logies are expected to improve during the [ADDRESS_1129071] ion.  
9.8.Biomarker s
Not applicable.
9.9.Health Economics
Not applicable.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129072] ical requirement.  However, thesample 
size (16 subjects for the control group and 8 subjects per group for the other groups )willprovide 
a 90% coverage probabilit y of the half -width of the 90% confidence interval wit hin 0.29 on a 
log-scale for comparison of each group to the control group forAUC or C max.Assuming the 
variability (coefficient of variat ion [CV]) is 32 %.  In the natural scale, assuming the ratio is r, the 
90% confidence interval for the ratio should be within (0.74r, 1.34r).
Subjectswho are enrolledbut not administered treatment may be replaced to ensure that a 
sufficient number of subjectscomplete the study .
10.2.Populations f or Analyses
10.2.1.Study Participant Disposition
A detailed descri ption ofsubject disposition will be provided at the end of the study .  All 
subjects who discontinue from the study  will be identified, and the extent of their participation in 
the study will be reported.  If known, a reason for their discont inuationwill be given.
10.2.2.Study Participant Characteristics
The subject’s age, sex, weight, height, smoking habits, or other demographic characteristics will 
be recorded and may  be used in the PK and safet y analyses as quant itative or classification 
variables.  Study participants’ renal status groupi[INVESTIGATOR_815430] a mean of the 
eGFR estimates, determined by [CONTACT_815453] m easurements of 
serum creatinine levels obtained onDay -1.
10.3.Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany or its 
designee.
Pharmacokinet ic analyses will be conducted on data fro m all subjects who receiveat least one 
dose of the IPand have eval uable PK.  
Safety analyses will be conducted for all enro lled subjects , whether or not they  completed all 
protocol requirements.
Immunogenicity analyses will be conducted for all subjects who receive at least one dose of IP.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129073] -hoc analyses and inco mplete disclosures of analyses.   
10.3.1.Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and ,if the frequency o f events allows, safet y 
data will be summarized using descript ive methodology.
The incidence of symptoms for each treatment will be presented by  [CONTACT_815454].  Symptoms reported to occur prior to study entry will be 
distinguished from those reported as new or increased in severi ty during the stud y.  Each 
symptom will be classified by  [CONTACT_57993] m the medical regulatory  dictionary.
The number of IP-related SAEs will be reported.
[IP_ADDRESS]. Statistical Evaluation of Safety
Safety parameters that will be assessed include safety  clinical laboratoryparameters(including 
amylase, lipase, and blood glucose) ,vital signs, physical examinat ions, and ECG parameters.  
The parameters will be listed and summarized using standard descriptive statist ics.  Physical 
examinations and ECGs willbe perform ed for safety monitoring purposes and will not be 
presented.   If warranted, a dditional analysis will be performed upon review of the data.
[IP_ADDRESS]. Injection-s ite Reaction s
Incidence of ery thema, induration, pain, itching, and swelling will be listed and summarized by  
[CONTACT_3148].  The post-injection pain score will be summarized by [CONTACT_3148].  Addit ional analyses 
may be performed, if appropriate.
10.3.2.Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for LY3298176 will be calculated by [CONTACT_72131].
The primary  parameters for analysis will be area under the concentration versus time curve
(AUC)from time zeroto infinity (AUC0-∞), AUC fro m time zero to the time of last measured 
concentration (AUC 0-tlast),and maximum drug concentration (C max).  Other nonco mpartmental 
parameters, such as half -life, apparent clearance, and apparent volume of distribut ion,may be 
reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
The mainanalysis is the e valuation of log-transformed AUC 0-∞, AUC0-tlast, and Cmaxusing an 
analysis of variance model with subject group asafixed factor.  The 90% confidence interval of 
the ratio between each impaired renal funct ion group versus the control group will be est imated.  
The above analyses will be conducted twice, using different renal funct ion group assignments 
(eGFR or creatinine clearance [CLcr] based on Day -1 measureme nts) (TableGPGG.3).  The 
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 44
LY3298176analysis based on CLcrwill be explorator y.  Additionally an exploratory  analysis based on 
Chronic Kidney  Disease Epi[INVESTIGATOR_10444] (CKD-EPI)method of renal impairment 
classification (Chronic Kidney  Disease Epi [INVESTIGATOR_454839], 2009) mayalso be 
performed.
TableGPGG.3. Renal Function Classification for Primary Analyses
Group Classification eGFR(mL/min/1.73m2)a CLcr (mL/min) b
1 Control (no rmal renal function) ≥90 ≥90
2 Mild renal impairment 60-89 60-89
3 Moderate renal impairment 30-59 30-59
4 Severe renal impairment <30, not requiring dialysis <30, not requiring dialysis
5 End-stage renal disease Requiring dialysis Requiring dialysis
Abbreviations:  CLcr=creatinine clearance; eGFR =estimated glomerular filtration rate.
aPer enrollment classification; eGFR will be calculat ed using the Modification of Diet in Renal Disease
abbreviated equation.
bCLcrwill be calculat ed using the Cockcroft -Gault formula ( Cockcroft and Gault 1976 ).
The supporting addit ionalanalysis is the evaluat ion of the relat ionship between the PK of 
LY3298176 and mean eGFR, as determined by [CONTACT_815455].  Scatter plots 
of PK parameter versus eGFR will be produced and analyzed using either a mixed -effects linear 
or a nonlinear regressio n approach witheGFR as a continuous covariate on PK parameters .  
Thetime to Cmaxwill be analyzed using a Wilcoxon rank sum test .
If a dose adjustmentafter interim is needed, descriptive statist ics for the PK param eters will be 
summarized by  [CONTACT_815456].  Dose normalizat ion or other methods may be employed 
for statistical  analyses. Details of methods will be described in the Statist ical Analysis Plan.
10.3.3.Pharmacodynamic Analyses
Not applicable .
10.3.4.Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
10.3.5.Evaluation of Immunogenicity
Subjects will be assessed for the development of TE ADA;the distribut ion of maximum titers 
will be described.  If cross-reactivity with native GLP-1and GIP or neutralizing ant ibodies 
against native GLP -1 and GIP assaysareperformed, the frequency of each will be reported .
The relationship between the presence of ant ibodies and the PKparameters and safety may be 
assessed.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 45
LY329817610.3.6.Data Review During the Study
Data may be analyzed while the tri al is ongoing.  An assessment committee will not be formed.   
Safety data will be reviewed by  [CONTACT_815457] a regular basis while subjects are 
enrolled in the study .
10.3.7.Interim Analyses
Interim analys es areplanned to occur during Study GPGG .FigureGPGG.3illustrates the 
interim data review decisio n tree.  
Two subjects each fro m Groups 2 and 3 (subjects with mild and moderate renal impairment, 
respectively ) andat least 2 subj ects in Group 1 (appropria te matched-control subjects with 
normal renal funct ion) will be enro lled in parallel and dosed with [ADDRESS_1129074] 2 subjects fro m 
Groups 4 and 5 (subjects with severe renal impairment and ESRD, respectively) and appropri ate 
matched-control subjects in Group 1.  
Asecond interim analysis to evaluate safet y, tolerability, and PK data will be performed forall 
subjects inGroup 3 (m oderate renal impairment) on completion of follow-up visit. Data from 
this interim will support Phase [ADDRESS_1129075] (Groups 4 and 5, respectively) and their applicable matched -control 
subjects (Group 1).
The purpose of the interim review(s) is to determine the dose level(s) for subsequent subjects.  
The dose of LY3298176 for subsequent subjects (any or all groups) may be adjusted accordingly 
after each interim. A reduced dose of approximately  50%is planned, if needed. The final dose 
determinat ions will be made by [CONTACT_815458].
If an addit ional unplanned interim analysis is deemed necessary , the Lilly  CP, CRP, investigator, 
or designee will consult wit h the appropriate medical director or d esignee to determine if it is 
necessary  to amend the protocol .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 46
LY3298176Abbreviations :  ESRD = end -stage renal disease;PK = pharmacok inetic; RI = renal impairment;
t-conference =teleconference.
*If the subjects with severe RI or ESRD are already being administe red a reduced dose,it may be necessary to 
discontinue enrollment of 1or both of these groups.
FigureGPGG.3. Interim data review decision tree.cv
cvcv
cv cv0
cvAt least [ADDRESS_1129076] 2 control subjects dosed at 
5.0 mg
Safety / PK review t-conference:
Dose tolerated?Yes
Yes
YesNo
NoContinue to dose mild/moderate RI subjects 
and dose first [ADDRESS_1129077] at 5.0 mgDose tolerated by [CONTACT_815459]?
Safety review t-conference following dosing 
of first [ADDRESS_1129078]: Dose tolerated?Dose not 
tolerated by 
[CONTACT_815460] 5.0 mg              
and reduce dose by 
[CONTACT_3450] 50% 
for remaining 
subjects with 
moderate RIReduce dose by 
[CONTACT_3450] 50% 
for remaining 
subjects with mild 
or moderate RI
Dose rem aining 
subjects with 
severe RI or 
ESRD at same 
dosePerform interim 
review and adjust 
dose for remaining 
subjects with      
severe RI 
or ESRD*Reduce dose by 
[CONTACT_3450] 50% 
for subjects with 
severe RI or ESRD
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 47
LY329817611.References
[ADA] American Diabetes Association .Defining and reporting hypoglycemia in diabetes: a
report from the American Diabetes Association Workgroup onHypoglycemia. Diabetes Care.
2005;28(5):1245 -1249.
[ADA] American Diabetes Association. 2017 Standards of medical care in diabetes: glycemic 
targets position statement. Diabetes Care. 2017:40(Suppl1):S48-S56.
Amori RE, Lau J, Pi[INVESTIGATOR_105319]. Efficacy  and safet y of incretin therapy in t ype 2 diabetes: 
systematic review and meta -analysis. JAMA. 2007;298(2):194 -206.
Baggio LL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroenterology . 
2007;132(6):[ADDRESS_1129079] therapi[INVESTIGATOR_36259] 2 diabetes. Ther Adv 
Endocrinol Metab . 2010;1(2):61 -67.
Chronic Kidney  Disease Epi [INVESTIGATOR_10444]. A new equation to estimate glomerular 
filtration rate. Ann Intern Med . 2009;150:604 -612.
Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum creatinine. Nephron. 
1976;16(1):31-41.
Drucker DJ, Nauck MA. The incretin system: glucagon -like peptide -1 receptor agoni sts and 
dipeptidyl peptidase-4 inhibitors in t ype 2 diabetes. Lancet. 2006;368(9548):1696- 1705.
Dungan KM, Povedano ST, Forst T, González JG, At isso C, Sealls W, Fahrbach JL. 
Once-weekly dulaglut ide versus once -daily liraglutide in metformin -treated pati ents with type 
2 diabetes (AWARD -6): a randomised, open -label, phase 3, non -inferiority trial. Lancet. 
2014;384(9951):1349-1357.
[EMEA CHMP] The European Medicines Agency Commit tee for Medicinal Products for 
Human Use. 2016. Guideline on the evaluation of pharmacokinet ics of medicinal products in 
patients with decreased renal funct ion.
[FDA] Food and Drug Administration. 2010. Guidance for Industry : Pharmacokinet ics in 
patients with impaired renal funct ion—study design, data analysis, and impact on dosing and 
labeling.
Finan B, Ma T, Ottaway  N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, 
Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruem mer D, 
Drucker DJ, Pfluger PT, Perez -Tilve D, Gidda J, Vignat i L, Zhang L, Hauptman JB, Lau M, 
Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde- Knape K, Konkar A, 
DiMarchi RD, Tschöp MH. Unimo lecular dual  incretins maximize metabo lic benefits in 
rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151.
Giorgino F, Benroubi  M, Sun J, Zimmermann AG, Pechtner V. Efficacy and safet y of once-
weekly dulaglut ide versus insulin glargine in pat ients with type 2 diabetes on m etformin and 
glimepi[INVESTIGATOR_14956] (AWARD -2). Diabetes Care . 2015;38(12):[ADDRESS_1129080] R, Bolton W, Shariff A, Green JB. Cardiovascular outcome trial update in diabetes: new 
evidence, remaining quest ions. Curr Diab Rep . 2017;17(9):67.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 48
LY3298176[IHSG] International Hypoglycaemia Study  Group. Glucose concentrations of less than 
3.0mmol/L (54 m g/dL) should be reported in clinical trials: a joint posit ion statement of the 
American Diabetes Associat ion and the European Associat ion for the Study  of Diabetes. 
Diabetes Care.2017;40(1):155 -157.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safet y of 
dulaglutide in the treatment of ty pe 2 diabetes: a com prehensive review of the dulaglut ide 
clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 
2016;32(8):776 -790.
Kim SJ, Ni an C, Karunakaran S, Clee SM, Isales CM, McIntosh CH. GIP -overexpressing mice 
demonstrate reduced diet -induced obesit y and steatosis, and improved glucose ho meostasis. 
PLoS One 7 . 2012;7(7):e40156.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. 
Chronic Kidney  Disease Epi [INVESTIGATOR_10444]. Using standardized serum creat inine 
values in the modificat ion of diet in renal disease study  equation for estimating glomerular 
filtration rate. Ann Intern Med. 2006;145(4):247 -54.
Nauck MA, Baller B, Meier JJ. Gastric inhibitory  polypept ide and glucagon -like peptide-1 in the 
pathogenesis of t ype 2 diabetes. Diabetes. 2004;53(suppl 3):S190 -S196
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, 
Matthews DR; LEAD -2 Study Group. Efficacy and safet y comparison of liraglut ide, 
glimepi[INVESTIGATOR_14956], and placebo, all in combinat ion with metformin, in ty pe 2 diabetes: the LEAD 
(liraglutide effect and act ion in diabetes) -2 study. Diabetes Care . 2009;32(1):[ADDRESS_1129081] ML, Jensen CB, Atkin 
SL; Study  1821 investigators. A Phase 2, randomized, dose -finding study  of the novel once-
weekly human GLP -1 analog, semaglut ide, compared with placebo and open -label liraglut ide 
in patients with t ype 2 diabetes. Diabetes Care . 2016;39(2):[ADDRESS_1129082] ER, Anderson J, Childs B, Cry er P, Dagogo -Jack S, Fish L, Heller SR, Rodriguez H, 
Rosenzweig J, Vigersky  R. Hypoglycemia and diabetes: a report of a workgroup of the 
American Diabetes Associat ion and the Endocrine Societ y. Diabetes Care . 
2013;36(5):1384 -1395.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 49
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibod ies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unint ended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC0-∞ area under the concentration versus time curve from time zeroto infinity
AUC0-tlast area under the concentration versus time curve from time zero to the time of last measured 
concentration
BP blood pressure
BMI body mass index
CKD-EPI [INVESTIGATOR_815431] A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by[CONTACT_815461].  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the st eps required to obtain 
confirmed results.
CP clinical pharmacologist
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 50
LY3298176CRF case report form
CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CRU clinical research unit
CSE clinically significant event
DPP dipeptidyl peptidase
ECG electrocardiogram
eGFR estimated glomerular filtration rate
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
enter Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable repr esentatives.
ERB ethical review board
ESRD end-stage renal disease
GCP good clinical practice
GI gastrointestinal
GIP glucose-dependent insulinotropic polypeptide
GLP-1 glucagon-like peptide -1
HbA1c hemoglobin A1c
HIV human immunodeficiency virus 
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonization
informed consent A process by [CONTACT_9444] a subject voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the subject’s decision to participate.  Informed consent is documented by [CONTACT_3553] a 
written, signed and dated informed consent form.  
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129083] :  A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical study , including products already on the market 
when used or assembled (formulated or packaged) in a way different from the authorized 
form, or marketed products used for an unauthorized indication, or marketed products used 
to gain further information about th e authorized form.
LS least squares
MDRD Modification of Diet in Renal Disease
NOAEL no-observed-adverse-effect level
open-label A study in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PG plasma glucose
PK pharmacokinetic(s)
QTc corrected QT interval
QW once weekly
RA receptor agonist
SAE serious adverse event
SC subcutaneous
Scr serum creatinine
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
S[LOCATION_003]Rs suspected unexpected serious adverse reactions 
T2DM type [ADDRESS_1129084] upper limit of normal
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 52
LY3298176Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a: Clinical Chemistry a:
Hematocrit Sodium
Hemoglobin Potassium
Erythrocyte count (RBC) Bicarbonate
Mean cell volume Chloride 
Mean cell hemoglobin Calcium 
Mean cell hemoglobin concentration Phosphorus
Leukocytes (WBC) Magnesium
Absolute counts of: Glucose, fasting
Neutrophils Blood urea nitrogen 
Lymphocytes Uric acid
Monocytes Total cholesterol
Eosinophils Triglycerides
Basophils Total protein
Platelets Albumin
Cell morphology b Total bilirubin
Alkaline phosphatase 
Aspartate aminotransferase 
Alanine aminotransferase 
Urinalysisa: Creatinine
Specific gravity Gamma-glutamyl transferase 
pH Amylase
Protein Lipase
Glucose
Ketones Ethanol testing d
Bilirubin Urine drug screen d
Urobilinogen Hepatitis B surface antigen c
Blood Hepatitis C antibody c
Nitrite HIVc
Microscopic examination of sediment b Pregnancy teste
FSHc,f
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus ;RBC = red blood cells; 
WBC = white blood cells.
aPerformed by [CONTACT_815462].
bIf clinically indicated , per investigator’s discretion .  
cPerformed by [CONTACT_543097] .
dUrine drug screen performed in clinic o r by [CONTACT_815463] .  Ethanol testing will be performed at admission to the clinical research unit.   Urine drug 
screen and ethanol level willbe repeated at other times indicated in the Schedule of Activities .  A serum or 
salivary drug screen may be performed on subjects who are unable to produce a urine sample.
eFemale subjects only.   Serum pregnancy test performed by [CONTACT_815464]; urine pregnancy tes t 
performed in clinic at all other times.
fFemale subjects only.   To confirm postmenopausal status as needed .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129085] igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r participation is voluntary.
ensuring that informed consent is given by [CONTACT_72140].  This 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF)prior to the performance of any  protocol procedures and prior to the administration 
of investigational product .
answering any quest ions the subject may  have throughout the study  and sharing in a 
timely manner any  new inform ation that may be relevant to the subject ’swillingness to 
continue his or her parti cipation in the study.
providing a copy  of the ICFto the parti cipant or the participant’s legal representative and 
retaining a copy on file.
Recruitment
Lilly or its designee is responsible for the central recruit ment strategy for subjects.  Individual 
investigators may have addit ional local requirements or processes.   Study-specific recruit ment 
material should be approved by [CONTACT_11007] .
Ethical Review
The investigator must give assurance that the ethical review board (ERB) was properly 
constituted and conven ed as requi red by [CONTACT_815465] (ICH)
guidelines and other applicable laws and regulations.
Documentation of ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study may begin at the investi gative site(s).  Lilly or its representatives must approve the ICF 
before it is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on good clinical practice ( GCP).
The study  site’s ERB(s) shoul d be provided wi th the following:
the current Investigator’s Brochure and updates during the course of the study
ICF
relevant curri cula vitae
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 54
LY3298176Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m international ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizations of Medical Sciences International Ethical Guidelines 
2)applicable ICH GCP Guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the planned design and conduct of the 
study.  
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Final Report Signature
[CONTACT_454896], indicating agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the most e nrolled subjects will serve as the final report coordinat ing 
investigator.  If this investigator is unable to fulfill this function, another invest igator will be 
chosen by [CONTACT_57998].
The sponsor’s responsi ble medical o fficer and statistician will sign/approve the final clinical 
study report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, com plete, and reliable data, Lilly  or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate.
provide training to i nstruct the invest igators and study  coordinators.  This training will 
give instructi on on the protocol, the complet ion of the case report forms ( CRFs), and 
study procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 55
LY3298176review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collection.
conduct a qualit y review of the database .
In addition, Lilly or its representatives willperiodically check a sample of the subjectdata 
recorded against sour ce documents at the study sit e.  The study  may be audited by [CONTACT_47557]/or 
regulatory agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include labor atory 
tests, medical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
documents.
Data Collection Tools/Source Data
An electronic data capture sy stem will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the s tudy will have control s and requi rements in accordance wit h local 
data protecti on law.  
The purpose and use of subject personal information collected will be provided in a written 
document to the subject by  [CONTACT_456].
Study and Site Closure
Discontinuation of Study Sites
Study site participation may be discont inuedif Lilly or its designee, the investigator, or the ERB 
of the study  sitejudges it necessary for medical, safety, regulatory , or other reasons consistent 
with applicable l aws, regulations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 56
LY3298176Appendix 4. Hepatic Monitoring Tests for 
Treatment -emergent Abnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may 
be required in fo llow-up with subjects in consultation with Lilly or its designeeclinical research 
physician .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocytes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated (direct)bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti-nuclear antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CK Anti-smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artateaminotransferase; CK = creat ine kinase; GGT = 
gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; 
WBC = white blood cells.
aAssayed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 57
LY3298176Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratories,and bioanaly tical assays) durin g thestudy.  
Protocol I8F-MC-GPGG Sampling Summary
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening testsa [ADDRESS_1129086] 10 mL 180
aAdditional samples may be drawn if needed for safety purposes.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 58
LY3298176Appendix 6. Pancreatic Monitoring
Glucagon-like peptide -1 (GLP-1)agonists have been associated with a possible risk of acute 
pancreatitis.  In2006, the US prescribing information for exenat ide was revised to include the 
event of pancreat itis.  In 2007, the US prescribing informat ion for this medication was am ended 
to include pancreat itis under precautions.  Epi[INVESTIGATOR_815432] o f pancreatitis in persons with type 2 diabetes mellitus 
(T2DM).
To enhance understanding of the natural variability o f pancreatic enzymes in the T2DM 
population and to assess for any  potential effects of LY3298176 on the exocrine pancreas, 
amylase and lipase values will be monitored in all current and future clinical trials wit h 
LY3298176 .
Additional monitoring will be requested for amylase or lipase values ≥3×upper limit of normal 
(ULN)at any visit postdose, even in asymptomat ic subjects (see figure below).  Lipase and 
amylase may also be obtained at any  time during the clinical trials for any  subject suspected of 
having sympt oms suggestive of pancreatit is (such as severe gastrointest inal signs and/or 
symptoms), at the invest igator’s discretion.
Acute pancreat itis is an adverse event defined as an acute inflammatory  process of the pancreas 
that may also involve peri pancreatic t issues and/or remote organ systems.  The diagnosis of acute 
pancreatitis requires 2 of the following 3features:
abdominal pain characteristic of acute pancreatit is
serum amylase and/or lipase >3 ×ULN
characterist ic findings of acute pancreat itis on computed tomography scan or 
magnetic resonance imaging
Most patients/subjects with acute pancreat itis experience abdo minal pain that is located generally 
in the epi[INVESTIGATOR_81075].  The pain is often 
associated with nausea and vo miting.  However, experience wit h GLP-1 agonists has 
demonstrated that som e patients/subjects asymptomat ic for classic pancreat itis may demo nstrate 
significant el evations of lipase and/or amylase.  For patients/subjects considered by [CONTACT_815466], but whose value(s) for lipase and/or amylase are ≥3×ULN, 
an algorithm is in place to fo llow these patients/subjects safely and to quickly  reach/or not a 
diagnosis of pancreat itis.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 59
LY3298176Pancreatic Enzymes :  Safety M onitoring Algorithm in 
Patients without Symptoms of Pancreatitis 1,2
Follow this algorithm when the value(s) for serum amylase and/or lipase are ≥3×upper limit of normal .
1.Symptomatic –related to abdominal pain consistent 
with pancreatitis; however, in the opi[INVESTIGATOR_1070], severe nausea and vomiting plus other 
symptoms consistent with pancreatitis may be 
considered symptomatic as well.
2.If in the opi[INVESTIGATOR_871], the subject has 
symptoms of acute pancreatitis:
(a)Discontinue subject
(b)Consult for assessment and management
(c)Assess for causes of pancreatitis
(d)Notify Lilly3.A/L = amylase and/or lipase .  Either or both 
enzymes can be used to meet algorithm criteria.
4.Abdominal imaging is most valuable when 
performed at the time of elevated enzym es.  If, in 
the opi[INVESTIGATOR_871], it is safe for the 
subject to receive contrast, and enhanced abdominal 
CT is preferred .  MRI is also an acceptable imaging 
modality.
5.At a minimum, order a CBC and a pancreatic panel 
(which includes LFTs, calcium , and trigycerides) .  
Record all concomitant medications
Abbreviations:  A/L = amylase and/or lipase; CBC = complete blood count; CT = computed tomography; 
LFT=liver function tests; MRI = magnetic resonance imaging; ULN = upper limit of normal.

I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129087] orclinical research 
physician.
Therapeutic Category Medication
Vitamin D compounds Doxercalciferol 
Anemia / iron deficiency Erythropoietin, intravenous or oral iron
Antihypertensives Beta blockers, ACE inhibitors, controlled release 
calcium channel blockers, angiotensin II receptor 
agonists 
Hypolipi[INVESTIGATOR_815433]-CoA reductase inhibitors (Atorv astatin, 
Simvastatin, Pravastatin, Fluvastatin) 
Antihyperuricemics Allopurinol 
Vasodilato rs Nitrates
Diuretics Furosemide, Hydrochlorothiazide, Spi[INVESTIGATOR_815434], calcium carbonate, Sevelamer
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 61
LY3298176Appendix 8. Calculation of Estimated Glomerular 
Filtration Rate
Calculation o f estimated glo merular filtrat ionrate(eGFR) from serum creat inine (Scr) assayed 
using an isotope dilut ion mass spectrometry  method and using the Modificat ion of Diet in Renal 
Disease abbreviated equation (Levey  et al. 2006).  The equation does not require weight or 
height variables because the results are reported normalized to an accepted average adult body 
surface area of 1.[ADDRESS_1129088] ion (eGFR 
<60mL/min/1.73 m 2) and has shown good performance for patients with all co mmon causes o f 
kidney disease .
eGFR (mL/min/1.73 m 2) =175× (Scr)-1.154× (Age)-0.203× (0.742 if fem ale) × (1.212 if African American)
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 62
LY3298176Appendix 9. Protocol A mendment I8F-MC-GPGG(b) 
Summary  
Pharmacokinetics of LY3298176 Following 
Administration to Subjects with Impaired Renal Function
Overview
Protocol I8F-MC-GPGG,Pharmacokinetics of LY3298176 Following Administration to 
Subjects with Impaired Renal Funct ion,has been amended.  The new protocol is indicated by  
[CONTACT_11827] ( b) and will be used to conduct the study  in place of any preceding version o f the 
protocol.
The overall changes and rationale for the changes made to th is protocol are as fo llows:
Based on early recruit ing experience with subjects with severe renal impairment, the 
protocol was amended to facilitate enro llment of subjects in Group 4.
oSevere renal impairment classificat ion is revisedto include subjects wi th eGFR 
<30mL/min/1.73m 2and not requiring dialysis, as defined in the EMEA guideline 
(EMEA CHMP 2016).
oSubjects with T2DMare now allowed to use insulin, outside of metformin.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page 63
LY3298176Revised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
1. Protocol Synopsis
Summary of Study Design:
Study I8F -MC-GPGG is a Phase 1, multicenter , nonrandomized, open-label, parallel -design study insubjects with 
mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD),and control subjects with normal 
renal function.  Renal function will provide the basis for assignment to treatment group.
Group 1: control subjects with normal renal function (e stimated glomerular filtration rate [ eGFR]
≥90mL/min/1.73m2)
Group 2: subjects with mild renal impairment ( eGFRbetween 60 and89mL/min/1.73m2)
Group 3:  subjects with moderate renal impairmen t (eGFR between 30 and 59 mL/min/1.73m2)
Group 4:  subjects with severe renal impairment (eGFR between 15 and 29 <30mL/min/1.73m 2and not 
requiringdialy sis)
Group 5:  subjects with ESRD (have received hemodialysis for at least 3 months).
5.1. Overall Design
TableGPGG.2. Subject Groups based on Renal Impairment Status
Classification eGFR (mL/min /1.73m2)
Group 1 Control (no rmal renal function) ≥90
Group 2 Mild renal impairment 60-89
Group 3 Moderate renal impairment 30-59
Group 4 Severe renal impairment 15-29<30 and not requiringdialy sis
Group 5 End-stage renal disease Requiring dialysis
Abbreviations :  eGFR = estimated glomerular filtration rate (as determined by [CONTACT_815438] ).
5.4. Scientific Rationale for Study Design
A comprehensive ra nge of renal impairment is necessary to fully characterize the impact of renal 
impairment on the PK of LY3298176.  Subjects undergoing hemodialysis (Group 5) will be 
included to determine the effect of dialysis on drug removal.
I8F-MC-GPGG(b)Clinical Pharmacology Protocol Page [ADDRESS_1129089]
[10]Males or females wit h stable mild to severe renal impairment, assessed by [CONTACT_815467] (having received hemodialysis for at l east 3 months).
6.1.4. Additional Inclusion Criteria f or Subjects with T2DM and Renal 
Impairment or ESRD
[13]Have T2DM controlledtreated with diet or exerci se alone or with stable doses of on
metformin and/orinsulinsfor at least 8 weeks.
[15]Have a hemoglo bin A1c (HbA1c) ≥7.06.0% and ≤11.0% at the screening visit.
6.2.3. Additional Exclusion Criteria for Subjects with T2DM and Renal 
Impairment or ESRD
[46]Have taken any glucose -lowering medicat ions other than metformin and/or insulins (refer 
to Inclusion Criterion [13]), including insulin, in the past 3 months before screening.  In 
general, stable dosages of metformin and insulins will be cont inued; however, a washout 
period or dose modificat ions may be necessary  to allow for optimal bl ood glucose
monitoring throughout the dosing period at the discr etion of the investi gator.
7.7. Concomitant Therapy
Stable single oral  doses of m etforminand/orstable doses of insulins (for at least 8 weeks) are 
allowed for subjects with T2DM.  Refer to Exclusion Criterion [46] in Sect ion 6.2.3.Additional 
concomitant medications for treatment of T2DM, other than metformin, are not permitted during 
the study.
TableGPGG.3. Renal Function Classification for Primary Analyses
Group Classification eGFR(mL/min/1.73m2)a CLcr (mL/min) b
1 Control (no rmal renal function) ≥90 ≥90
2 Mild renal impairment 60-89 60-89
3 Moderate renal impairment 30-59 30-59
4 Severe renal impairment 15-29<30, not requiring 
dialysis15-29<30, not requiring 
dialysis
5 End-stage renal disease Requiring dialysis Requiring dialysis
Abbreviations:  CLcr=creatinine clearance; eGFR =estimated glomerular filtration rate.
aPer enrollment classification; eGFR will be calculat ed using the Modification of Diet in Renal Disease 
abbreviated equation.
bCLcrwill be calculat ed using the Cockcroft -Gault formula ( Cockcroft and Gault 1976 ).
Leo Document ID = a4c382cc-21ac-4798-a6a3-c1f096dfe2d1
Approver: 
Approval Date & Time: 03-May-2019 14:26:52 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 03-May-2019 15:03:22 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]